drugset

drugset / Trial / NCT00122304

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

NCT00122304 ↗

Phase 3 Completed 85 enrolled Alexion Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH

Timeline

Start: 2004-12
Primary completion: —
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eculizumab	Monoclonal antibody	—	—

Indications